A low frequency ultrasound-based method to minimize nephrotoxicity induced by radiographic contrast media (e.g. contrast agent or dye) when using diagnostic tests such as MRI, CT scans, and angiograms.
Diagnostic medical imaging— in large part MRI, CT, and PET — is a pillar of modern medicine and it is heavily being used in the US healthcare system. Despite the proven clinical benefits of medical imaging, it is not risk free; radiographic contrast media is necessary to perform many of the diagnostic tests. The contrast media can particularly affect the kidneys and result in a rare condition known as contrast material-induced nephropathy (CIN) — patients with chronic kidney disease, diabetes, and history of heart disease are at higher risk to suffer from this condition. In order to mitigate the risks associated with X-ray imaging, clinicians invested major efforts in identifying effective preventive interventions for CIN. Several of the approaches tested in clinical setting — such as administration of pharmacological agents — to offset the nephrotoxic effects have yielded inconsistent results, thus a new approach is warranted.
UCSF investigators have demonstrated that applying low-frequency ultrasound stimulates endothelial nitric oxide synthese activity, which promotes the release of nitric oxide (NO) in preclinical models. NO functions as a vasodilator that enhances medullary perfusion and prevents reactive oxygen species-mediated kidney injury. The inventors translate their findings to clinical setting by describing the following noninvasive approach: 1) the system may comprise of two transducers separately applying low frequency ultrasound to each kidney without interfering with x-ray imaging; 2) patients would receive treatment prior to, during, or following administration of radiographic contrast media; and 3) this technology can be designed as a stationary or a wearable device dependence on clinical requirements. Overall, this technology has potential to provide an effective and safe remedy for CIN.
Treatment for radiographic contrast material-induced nephropathy
To develop and commercialize this technology as a method of reducing nephrotoxic effects induced by radiographic contrast material
Michael Dae: http://profiles.ucsf.edu/michael.dae
|United States Of America||Issued Patent||10,328,287||06/25/2019||2011-038|
|United States Of America||Issued Patent||9,420,990||08/23/2016||2011-038|
|United States Of America||Issued Patent||8,585,597||11/19/2013||2011-038|